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Summary
Transfusion of blood components with residual leukocytes may lead to a number of adverse 
reactions based on two separate immune-mediated mechanisms. Such complications include 
transfusion associated — graft versus host disease (TA-GvHD), febrile nonhemolytic trans-
fusion reactions (FNHTRs), which are caused by release of cytokines and recipient alloim-
munization with HLA antigens. This leads to anti-HLA antibody formation in the recipient 
and may induce refractory response to the transfused platelet concentrate (PC). To reduce the 
risk of transferring residual leukocytes with transfused blood components, for many years now 
various preparation methods have been applied, which contribute to reduction of white blood 
cell (WBC) count or to leukocyte inactivation. These include: leukoreduction, gamma irradia-
tion and pathogen inactivation methods. Advancement of research on pathogen inactivation 
in blood components has demonstrated that some of the methods used for the routine pathogen 
inactivation in plasma and platelet concentrate (Mirasol®PRT system and Intercept) may also 
be effective for inactivation of T lymphocytes. These methods may therefore serve as alternative 
to irradiation. Also the inactivation method with UVC light when implemented into routine 
use, may replace the commonly used irradiator. Inactivation methods were found not only 
effective for protection against TA-GvHD, but also for inhibiting cytokine synthesis, primarily 
responsible for febrile nonhemolytic transfusion reactions. 
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Serious adverse reactions
Transfusion of leukocyte-contaminated blood 
components may induce adverse reactions based on 
two separate immune-mediated mechanisms. One of 
these mechanisms occurs when leukocytes present in 
the transfused blood components stimulate the recipi-
ent’s cells and tissues to induce acute post transfu-
sion reactions such as Transfusion Associated-Graft 
versus Host Diseases (TA-GvHD) or Febrile Non 
Hemolytic Transfusion Reactions (FNHTRs) caused 
by cytokine release. In the other mechanism, recipi-
ent’s T cells recognize foreign HLA antigens on donor 
leukocytes. In the presence of the molecules of the 
major histocompatibility complex (MHC)  on donor 
antigen presenting cells (APC) (direct pathway) or 
recipient antigen presenting cells (indirect pathway) 
donor T cells  recognize unknown HLA antigens. 
Recognition of foreign HLA donor antigen by recipi-
ent’s T cells lead to anti-HLA antibody formation in 
the recipient, which may induce the patient’s refrac-
toriness to transfused platelet concentrate (PC).
To reduce the risk of transferring residual 
leukocytes with transfused blood components, for 
many years now various preparation methods have 
been applied the result of which is either reduc-
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tion of white blood cell (WBC) count or leukocyte 
inactivation. These methods serve to protect blood 
component recipients against alloimmunization 
with HLA antigens, FNHTRs or TA-GvHD. Hae-
movigilance data (HV, haemovigilance) at both 
national and European level demonstrates that 
even small numbers of leukocytes in the transfused 
blood components may be sufficient to induce 
severe adverse post-transfusion reactions in the 
recipient (Table 1) [1, 2].
Transfusion-associated graft  
versus host disease
Transfusion-associated graft versus host dis-
ease (TA-GvHD) is one of the most severe adverse 
reactions which may result either from transfusion 
of immunocompetent donor T cells (which the 
recipient’s immune system is unable to destroy) 
or else the donor is homozygous for one of the re-
cipient’s HLA haplotypes. TA-GvHD occurs when 
the recipient’s tissues are damaged as result of the 
interaction between donor and recipient cells of 
the immune system. Various lymphocyte  subsets 
such as interleukins, pro-inflammatory cytokines 
and adhesion particles are involved in the process 
of host-cell damage following transfusion of lym-
phocyte contaminated blood components. First, 
the recipient’s dendritic cells and macrophages, 
which function as APC cells, present HLA antigens 
to transfused T lymphocytes. Interleukin-1 (IL-1) 
secreted by macrophages and the thymocyte-
stimulating factor activate helper CD4 + T cells 
to secrete interleukin-2 (IL-2) which in turn 
stimulates CD 8+ lymphocytes. Activation of T 
lymphocytes stimulates the release of cytokines 
from various cells, resulting in clonal proliferation 
of T lymphocytes, which differentiate into cytolytic 
cells or lymphokine secreting cells. At this stage, 
there occurs an uncontrolled robust generation of 
cytokines with direct impact on recipient’s target 
cells, or indirect impact through stimulation of cells 
of the hematopoietic line, such as B lymphocytes, 
cytotoxic lymphocytes or macrophages. These 
cells act as secondary affectors and, together with 
cytokines, are responsible for damage and death of 
the recipient’s target cell [3, 4].
According to the reports of Serious Hazards of 
Transfusion (SHOT), TA-GvHD is relatively rare 
with the incidence rate of approximately 0.1–1% 
of all adverse reactions and mostly observed in 
patients with haematopoietic hyperplasia and 
lymphoproliferative disorders. The complication 
is a serious problem in clinical practice because 
there is no effective treatment and the mortality 
rate is high (> 90%). Moreover, even new genera-
tion leukocyte-removal filters offer no protection 
against development of TA-GvHD because the 
residual leukocyte count in blood components 
(< 1 × 106) is sufficient to induce the reaction. So 
far, the only effective method of protecting at risk-
-patients against development of TA-GvHD was 
to subject cellular blood components to gamma or 
X-ray irradiation (Cs137, Co60 or X) [5–9].
Advancement of research on pathogen inac-
tivation in blood components demonstrated that 
some of the methods used for the purpose may 
also be effective for inactivation of T lympho-
cytes. These methods may therefore serve as 
alternative to irradiation [10]. The principle is to 
induce irreversible changes in the nucleic acids 
of viruses, bacteria, parasites and leukocytes by 
inhibiting their multiplication. In world literature 
there are reports on the effectiveness of white 
blood cell inactivation in PCs with routinely used 
pathogen inactivation systems (Intercept and 
Mirasol) and therefore the possibility of replac-
ing irradiated PC with PC inactivated with one 
of the above-mentioned systems has also been 
confirmed. Some countries (France, Spain, Austria, 
Luxembourg, Qatar, Poland) use Mirasol®PRT 
system or Intercept systems for inactivation of 
pathogens in PCs dedicated for patients at risk of 
Table 1. Serious adverse reactions after transfusion of blood components
Adverse reactions Responsible factor
Transfusion Associated-Graft versus Host Disease, TA-GvHD Immunocompetent donor T cells
Alloimmunization with HLA antigens Donor leukocytes
Febrile nonhemolytic transfusion reaction, FNTHR Cytokines released from donor leukocytes
Transfusion related acute lung injury, TRALI Donor/recipient antibodies (anti-HLA class I or class II  
and anti-granulocytic antibodies)
Pathogen transmision Infectious agents associated with leukocytes (e.g. CMV, 
HTLV 1/2)
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TA-GvHD. Irradiation of already inactivated PCs 
is not recommended [11]. 
Results of numerous studies confirm the meth-
ods of pathogen inactivation for red blood cells or 
whole blood (PEN 110, S-303, riboflavin) — under 
development or in course of clinical trials — to be 
equally effective for inactivation of white blood 
cells [12]. If implemented for routine use, these 
methods could replace the currently used gamma 
or X-ray irradiation. Pursuant to the guidelines of 
the National Atomic Energy Agency (PAA) and 
in view of the mounting threat of terroristic at-
tacks the operation and management of radiators 
requires continuous monitoring of this radioactive 
source. In addition, gamma irradiation reduces the 
functional inactivation of red blood cells (leakage of 
intracellular potassium into extracellular space, he-
molysis), which intensify with time. It is therefore 
recommended to irradiate (radiators) blood compo-
nents for patients at risk of developing TA-GvHD 
immediately before transfusion (Table 2). Some 
study results on inactivation of leukocytes either 
with routinely used systems or with methods still 
under trial suggest that — apart from preventing 
TA-GvHD — these methods are also effective for 
prevention of alloimmunization with HLA antigens 
as well as febrile nonhemolytic transfusion reac-
tions (FNHTR) [13, 14].
Alloimmunization
The TRAP (Trial to Reduce Alloimmuniza-
tion to Platelets) reports no platelet recovery 
in the recipient’s circulation both after 1 and 24 
hours of PC transfusion which meant that the 
frequency of transfusions had to be higher. There 
were attempts to explain the phenomenon by the 
appearance of antibodies in the recipient, but the 
results of lymphocytotoxicity tests demonstrated 
that reduced platelet recovery occurs both in the 
presence and absence of anti-leukocyte antibod-
ies. Repeat analysis of data demonstrated that 
the differences in the number of recipient platelet 
cells depended on the type of PC transfused. 
Higher platelet recovery was observed following 
transfusion of leukoreduced or UV-irradiated PC 
than after transfusing standard PC. Therefore 
leukocyte-contaminated PCs were considered the 
most likely cause of alloimmunization with HLA 
antigens responsible for resistance to transfused 
PCs which occurs in patients subjected to multi- 
ple PC transfusions. Numerous studies have 
however confirmed, that gamma irradiation is no 
protection against alloantibody formation. One 
of the management procedures currently used is 
transfusion of leukoreduced PCs or HLA compat-
ible PCs. These procedures however, are not in 
routine use [15–17].
Febrile nonhemolytic transfusion reaction
Febrile nonhemolytic transfusion reactions 
(FNTHR) following PC transfusion are most of-
ten caused by the presence of leukocytes in the 
transfused blood component and anti-leukocyte 
antibodies detected in recepients. Recipient’s 
macrophages are activated as a result of the anti-
gen-antibody-complement reaction. These interac-
tions induce cytokine secretion at concentrations 
proportional to the number of leukocytes in PC 
as well as duration of storage prior to transfu-
sion. Heddle demonstrated that elevated levels of 
interleukin-1beta (IL-1b) and interleukin-6 (IL-6) 
in stored PCs are the most common causes of 
FNTHR. The adverse reaction can be prevented 
by leukocyte removal no later than 6 hours of PC 
preparation [18]. 
The incidence rate for FNHTR following trans-
fusion of non-leukoreduced red blood cells is esti-
mated at 0.12 to 0.5%, while for non-leukoreduced 
PCs it is significantly higher, from 1.7 to 31%. The 
relationship between high content of IL-1a, IL-6 
Table 2. Patients at risk of TA-GvHD broken down into probability of occurrence
Proven risk Possible risk Unspecified risk
• Recipients of allo- and autologous 
bone marrow transplants 
• Persons with congenital immune 
deficiencies
• Intrauterine transfusion 
• Persons receiving blood components 
from related persons (1st and 2nd 
degree)
• Persons with Hodgkin’s disease 
• Premature babies 
• Persons with haematological 
diseases other than Hodgkin’s 
disease
• Persons with solid tumors
• persons after organ transplantation
• AIDS
• Neonates born on time
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and TNF-a and that of white blood cells in PC above 
3 × 106/l was also confirmed. Although filtration 
or plasma removal significantly contributes to 
reduction of cytokine concentration and therefore 
reduction of the incidence rate for FNTHR, adverse 
reactions due to leukocyte contamination sporadi-
cally occur despite leukoreduced PCs. Muylle et 
al. performed analyses of transfusion procedures in 
45 patients who were transfused with leukoreduced 
PC and yet 13% of them presented a feverish reac-
tion due to significant increase in TNF-al and IL-6 
in UKKP [2, 19, 20].
Apart from secretion of leukocyte-derived 
cytokins during PC storage there also occurs 
the secretion of alpha granules and granular 
platelet chemokine cells that induce allergic 
reactions. These include platelet-derived: CCL3 
(MIP-1, macrophage inflammatory protein), CCL5 
(RANTES, regulated upon activation and normal 
T cell expressed and secreted), CXCL4 (PF4, 
platelet factor4), TGF-beta1-transforming growth 
factor beta 1. Some of these cytokines, e.g. CCL5 
(RANTES) are involved in non-haemolytic, allergic 
or pro-inflammatory reactions following transfusion 
of leukoreduced PCs induced — among others — by 
their ability to attract and stimulate human eosino-
phils and to induce histamine secretion from human 
basophils. For allergic reactions, the RANTES range 
was estimated at 200–1000 ng/ml [21–23].
Transfusion related acute lung injury
Transfusion related acute lung injury (TRALI) 
is a very severe adverse reaction characterized by 
breath shortage (pulmonary edema with hypoxia). 
It may occur during transfusion or up to 72 hours 
of the procedure. Untreated TRALI leads to death 
in approximately 25% of patients. The incidence 
rate for TRALI is estimated at about 1/1500–5000 
transfusions although the exact data is unavailable. 
At exceptionally high risk are patients in critical 
condition (6–8%). TRALI syndrome has been re-
ported after transfusion of all types of blood com-
ponents as well as intravenous administration of 
immunoglobulins. TRALI pathogenesis is not fully 
recognized. In most cases, the syndrome is induced 
by leukocyte antibodies, most often anti-HLA class 
I and II or specific anti-human neutrophil antigen 
(anti-HNA-1a, 1b, 2a, 3a) antibodies. Not only anti-
leukocyte antibodies are responsible for neutrophil 
activation in transfused blood components but also 
biologically active lipids, lysophosphatidylcholine 
(L-PC) or cytokines that accumulate during storage 
of blood components [24–26].
Leukocyte contamination and methods  
of pathogen inactivation 
Leukocyte inactivation with the use  
of the Mirasol®PRT system
Results of numerous studies have con-
firmed that the inactivation method used in the 
Mirasol®PRT system is also effective for leuko-
cytes, including T lymphocytes, the transfusion of 
which (via blood components) puts the recipient at 
risk of TA-GvHD. The degree of T cell inactiva-
tion was determined using — among others — the 
limiting dilution assay (LDA) or by measurement 
of CD69 antigen expression, an early marker of T 
cell activation involved in transfer of the activa-
tion signal, which leads to the synthesis of various 
cytokines (including IL-2, INF-g). 
The LDA method revealed that following inac-
tivation with the Mirasol®PRT system the number 
of viable T cells decreased by over 6 logs. It was 
also determined that the Mirasol®PRT system is 
effective for inhibiting T lymphocyte activation, as 
demonstrated by complete lack of CD69 expression 
on cells inactivated with this system (1.7 ± 1.3%) 
as compared to CD69 expression on control cells 
(64.4 ± 15.6%) [27].
Numerous in vitro studies also demonstrate 
that leukocytes inactivated in the Mirasol®PRT 
system are not capable of stimulating or binding 
allogeneic cells. Unlike leukocytes exposed to 
gamma irradiation, leukocytes inactivated in the 
Mirasol®PRT system were observed to lose their 
ability to act as antigen presenting cells (APCs). 
This is most likely due to significant reduction in 
the expression of some surface receptors such as 
HLA-DR, ICAM 1-3, CD80, and CD86 responsible 
for activation and adhesion of T lymphocytes. 
A slight reduction in the expression of HLA class II 
surface antigens and co-stimulatory molecules was 
observed in leukocytes inactivated with riboflavin 
and UV light as well as a significant reduction in 
expression of numerous adhesion molecules in 
antigen presenting cells. Almost complete loss of 
immunogenicity has also been observed [28].
Studies were performed to verify whether the 
Mirasol®PRT system is effective for reducing the 
risk of febrile nonhemolytic transfusion reactions 
(FNTHR). A significant inhibition of the synthesis 
of cytokines: IL-2, IL-4, IL-5, IL-6, IL-10, IFN-g, 
IL-1b, IL-12p70 was observed in mononuclear 
cells inactivated in the Mirasol® PRT system as 
compared to control mononuclear cells and mono-
nuclear cells subjected to irradiation [29].
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Inactivation of leukocytes using  
the Intercept system
Even the first results of in vitro and in vivo 
studies have already confirmed the method based 
on the use of amotosalen hydrochloride and UVA 
to be effective also for inactivation of leukocytes, 
mononuclear cells (MNCs), T lymphocytes in 
particular. Following LDA in PC samples collected 
after pathogen inactivation with the Intercept sys-
tem (150 µM S-59 and 3 J/cm2), a 5.4 log decrease 
in the number of viable T lymphocytes was ob-
served and no T lymphocyte colony-formation was 
confirmed. Additional studies with lower doses of 
amotosalen hydrochloride (S-59) were performed 
in order to determine the safety margin for the 
photochemical method with regard to T cells. The 
studies have demonstrated exceptional sensitivity 
of T lymphocytes to the photochemical method. 
Amotosalen hydrochloride at a dose 1500–3000 fold 
lower than normally used in the Intercept system 
and 2 fold lower UV dose than the virucidal dose 
were sufficient to inactivate T lymphocytes to limit 
of detection. 
Like the Mirasol®PRT system, the Intercept 
system, inhibits CD 69 expression. Fiebig et al. 
determined CD69 antigen expression in control 
PC samples, in PC samples exposed to gamma ir-
radiation and samples inactivated in the Intercept 
system. Immediate reduction of CD69 expression 
was observed in T lymphocytes exposed to gamma 
irradiation and those inactivated in the Intercept 
system to 21% and 12% respectively. In the control 
group, the average expression was 82%) [30, 31]. 
In vitro studies also confirmed the Intercept 
system to be effective for inhibition of cytokine 
synthesis. Interleukin-8 (IL-8) concentration was 
compared in 3 types of PCs stored for up to 7 days 
(control PC, PC exposed to gamma irradiation and 
PC inactivated in the Intercept system). A signifi-
cantly higher IL-8 concentration was reported for 
control PCs and in PCs subjected to irradiation. 
In their studies Hei et al. confirmed the Intercept 
system to inhibit the synthesis of IL-8, IL-1b, 
TNF-a and IL-6. It should be emphasized, that 
also bacteria contribute to cytokine secretion and 
inactivation of bacteria with the Intercept system 
prior to PC storage is an additional preventive 
measure against hemolytic febrile transfusion reac-
tions. Research from numerous scientific centers 
has confirmed the Intercept system to completely 
inhibit the synthesis of cytokines and — unlike 
gamma irradiation which reduces the synthesis 
of cytokines by only 40% — it provides additional 
protection against the development of FNTHR 
[22, 23, 32, 33].
Leukocyte Inactivation with other 
pathogen inactivation methods 
Theraflex UV-Platelets based on UVC light 
is a method not as yet implemented for routine 
use but already evaluated and found effective for 
inactivation of white blood cells. Results of the first 
studies performed on xenogenic mouse models in-
dicate that UVC used in the Theraflex MB Plasma 
UV-Platelets system is as effective as the routine 
gamma irradiation. Even half the routine dose of 
UVC has been found to inactivate T lymphocytes. 
Paralel in vitro studies demonstrated no prolifera-
tion of mononuclear white blood cells (following 
PHA, anti CD3 and anti CD28 stimulation in mixed 
lymphocyte culture) when 0.1 J/cm2 and 0.2 J/cm2 
were used (the latter dose is routinely used in 
Theraflex UVC system). This indicates that the 
lower dose of 0.1 J/cm2 is absolutely sufficient to 
inhibit the proliferative capacity of mononucle-
ated white blood cells, in contrast to mononuclear 
white blood cells isolated from PCs exposed to 
gamma irradiation. It can therefore be assumed 
that UVC irradiation prevents proliferation of T 
lymphocytes responsible for the development of 
TA-GvHD [34, 35].
It also turned out that UVC light, even at 
a dose of 0.1 J/cm2, protects antigen presenting 
cells against stimulation with allogeneic cells. It 
seems likely therefore, that the UVC light-based 
method offers protection against alloimmunity. 
Deterioration of direct antigen presentation by 
antigen presenting cells (APCs) may result either 
from the decrease in the expression of critical 
surface receptors for T lymphocyte activation and 
adhesion (characteristic for prevention of alloim-
munization in the Mirasol®PRT system) or from 
defect in antigen processing [28].
UVC irradiation has also been found effective 
for significant IL-1b and IL-6 cytokines reduction. 
Strong inhibition of cytokine secretion already 
occurred after application of the UVC light at 
a dose — 0.1 J/cm2 (which is half the routine dose of 
0.2 J/cm2) in PCs subjected to inactivation. Synthe-
sis of IL-8, a cytokine secreted during PC storage, 
was also significantly inhibited after application of 
UVC light [18].
The Mirasol®PRT system developed for 
pathogen inactivation in whole blood has also 
been found effective with regard to leukocytes. 
Using 33 or 44 J/ml RBC energy, inactivation of 
118 www.jtm.viamedica.pl
Journal of Transfusion Medicine 2020, tom 13, nr 2
mononucleated cells (isolated from whole blood) 
was found. Human T cells previously inactivated 
in the Mirasol®PRT system were transplanted into 
mice which did not develop GVHD. This indicates 
that the Mirasol®PRT system may be an alterna-
tive to whole-blood irradiation. 
Summary
Results from various research centers deal-
ing with pathogen inactivation methods in blood 
components which are presented in this review 
confirm that most of these methods have also been 
proved effective for inactivation of leukocytes re-
sponsible for many serious adverse reactions. The 
methods used in Mirasol®PRT system and Inter-
cept systems currently in routine use for pathogen 
inactivation in plasma and PC have also been found 
effective for inactivation of T lymphocytes. These 
methods therefore may be regarded as an alterna-
tive to irradiation. Once the method of inactivation 
based on the use of UVC light is implemented for 
routine use, it will also replace a commonly used 
irradiation method. It was also demonstrated that 
inactivation methods not only protect against TA-
GvHD, but also inhibit the synthesis of cytokines, 
which are primarily responsible for transfusion 
related non hemolytic febrile reactions.
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